Literature DB >> 9523382

Sex hormones in spondylarthropathies. A study in 57 patients.

D Arniaud1, J P Mattei, J Boyer, H Roux.   

Abstract

Studies of the hormonal status of patients with spondylarthropathies are few in number, despite the predominantly male sex ratio characteristic of these diseases. Most suggested an elevation in androgen levels. We determined the following parameters in 57 men with spondylarthropathies: FSH, LH, prolactin, estradiol, total testosterone, free testosterone, delta-4-androstenedione, 17-OH-progesterone, estradiol over total testosterone ratio and estradiol over free testosterone ratio. Results were compared to those in a group of 100 healthy controls. Mean patient age was 41.9 years, and mean disease duration was one year. None of the patients were under corticosteroid therapy. The mean prolactin level was normal (8.4 +/- 4.5 ng/ml), whereas the mean 17-OH-progesterone level was significantly elevated (2.02 +/- 0.8 ng/ml). The estradiol over testosterone ratios were normal. This hormone profile is consistent with partial deficiency in the enzyme 21-hydroxylase, which is encoded by a gene located on chromosome 6 only 600 kb away from the HLA B locus. We suggest that some class I alleles may be associated with an alteration in 21-hydroxylase responsible for an increase in 17-OH-progesterone levels and for macrophage inhibition resulting in delayed elimination of antigens. This hypothesis is consistent with the possibility raised by others that macrophage inhibition may explain the increased prevalence of infections due to intracellular organisms in patients with spondylarthropathies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523382

Source DB:  PubMed          Journal:  Rev Rhum Engl Ed        ISSN: 1169-8446


  2 in total

1.  Hypothalamic-pituitary-adrenal axis function in ankylosing spondylitis.

Authors:  R Imrich; J Rovensky; M Zlnay; Z Radikova; L Macho; M Vigas; J Koska
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

2.  Estrogen attenuates the spondyloarthritis manifestations of the SKG arthritis model.

Authors:  Hyemin Jeong; Eun-Kyung Bae; Hunnyun Kim; Yeong Hee Eun; In Young Kim; Hyungjin Kim; Jaejoon Lee; Chan Hong Jeon; Eun-Mi Koh; Hoon-Suk Cha
Journal:  Arthritis Res Ther       Date:  2017-09-07       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.